Abstract #3079

In-vivo imaging of glutamine metabolism to the oncometabolite 2-hydroxyglutarate in IDH1/2 mutant tumors

Lucia Salamanca-Cardona^1,2, Alex J. Poot^1,2, Valentina Di Gialleonardo^1,2, Fabian M. Correa^1,2, Hardik Shah³, Hui Liu³, Vesselin Z. Miloushev¹, Kristin L. Granlund^1,2, Justin R. Cross³, Craig B. Thompson⁴, and Kayvan R. Keshari^1,2

¹Radiology, Memorial Sloan Kettering Cancer Center, New York City, NY, United States, ²Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York City, NY, United States, ³Donald B. and Catherine C. Marron Cancer Metabolism Center, Memorial Sloan Kettering Cancer Center, New York City, NY, United States, ⁴Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York City, NY, United States

2-hydroxyglutarate (2-HG) is an oncometabolite that accumulates in various cancers as a result of mutations in the isocitrate dehydrogenase (IDH1/2) genes and can be used as a biomarker for diagnosis. In this work, we demonstrate the fast conversion of glutamine to 2-HG and use it as a basis for developing a 2-HG in-vivo detection method. Using hyperpolarized [1-¹³C] glutamine and magnetic resonance imaging (MRI), we present the non-invasive unambiguous detection of 2-HG formation with high specificity from glutamine in-vivo and real-time in IDH1 and IDH2 mutant tumors.

This abstract and the presentation materials are available to members only; a login is required.

Join Here